Clinical Trials in Chicago

Showing 5781-5800 of 15,574 trials

A Long-term Treatment With B-VEC for Dystrophic Epidermolysis Bullosa

NCT04917874

This is a 112-week (approximately two-year) open-label extension study of Beremagene Geperpavec (B-VEC), for participants aged 2 months and older, who have been diagnosed with Dystrophic Epidermolysis Bullosa (DEB). Participants will be dosed weekly with the topical B-VEC therapy. The primary endpoint will be to assess long term safety and tolerability of the topical gene therapy. The study is for those who participated in Phase 3 study, as well as, new participants who were unable to participate in the Phase 3 study, who meet all enrollment criteria.

Dystrophic Epidermolysis BullosaDEB - Dystrophic Epidermolysis BullosaRecessive Dystrophic Epidermolysis Bullosa+1 more

Krystal Biotech, Inc.47 participantsStarted May 2021

Rancho Santa Margarita, California, United States • Redwood City, California, United States • Coral Gables, Florida, United States +3 more locations

TERMINATEDPhase 1/22.2 miles

Allogeneic Heart Stem Cells to Achieve Myocardial Regeneration

NCT01458405

The purpose of this study is to determine whether Allogeneic Cardiosphere-Derived Cells (CAP-1002) is safe and effective in decreasing infarct size in patients with a myocardial infarction.

Myocardial Infarction

Capricor Inc.135 participantsStarted Nov 2012

Birmingham, Alabama, United States • Huntsville, Alabama, United States • La Jolla, California, United States +29 more locations

A Long-term Treatment With B-VEC for Dystrophic Epidermolysis Bullosa

Allogeneic Heart Stem Cells to Achieve Myocardial Regeneration

Find Trials by Condition in Chicago

Treatment Effects of Subcutaneous Injections of Pentosan Polysulfate Sodium vs Placebo in Participants With Knee OA Pain

Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LAVENDER™)

Oxytocin and Social Cognitive Skills Groups

COVID-19 & Psychiatry: A Retrospective Chart Review

Sirolimus Treatment in Hospitalized Patients With COVID-19 Pneumonia

Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)

TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801)

Study to Compare the Efficacy and Safety of Enzyme Replacement Therapies Avalglucosidase Alfa and Alglucosidase Alfa Administered Every Other Week in Patients With Late-onset Pompe Disease Who Have Not Been Previously Treated for Pompe Disease

A Nutritional Supplement on Vasomotor Symptoms in Women

Study to Evaluate Safety, PK, PD, Immunogenicity & Antitumor Activity of MSC-1 in Patients With Adv Solid Tumors

An Evaluation of the Efficacy and Safety of CSF-1 in the Temporary Correction of Presbyopia (NEAR-2)

A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts

Spiration Valves Against Standard Therapy

Retrospective Evaluation of SuperSaturated Oxygen (SSO2) Therapy Clinical Utility

Safety and Effectiveness of GP0112 for Cheek Augmentation and Correction of Midface Contour Deficiencies

Evaluation of Product Performance of a New Silicone Hydrogel Multifocal Contact Lens

A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract

An Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma